Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 10/20 | 0.60 |
| ▸ | F10 | P00742 | 10/20 | 0.60 |
| ▸ | F7 | P08709 | 2/20 | 0.60 |
| ▸ | PLAU | P00749 | 9/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.56 |
| ▸ | PLG | P00747 | 8/20 | 0.56 |
| ▸ | PLAT | P00750 | 8/20 | 0.56 |
| ▸ | HPN | P05981 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | UBE2N | P61088 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | F9 | P00740 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408233 | 0.92 | F2 (0.55) | F2F10F7PLAUPRSS1 | |
| SCHEMBL23201240 | 0.91 | F2 (0.54) | F2F10F7PLAUPRSS1 | |
| SCHEMBL30882746 | 0.91 | F2 (0.54) | F2F10F7PLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL31364563 | 0.90 | F2 (0.53) | F2F10F7PLAUPRSS1 | |
| SCHEMBL23793811 | 0.89 | F10 (0.50) | F2F10F7PLAUPRSS1 | |
| SCHEMBL23793906 | 0.87 | F2 (0.51) | F2F10F7PLAUPRSS1 | |
| SCHEMBL7405355 | 0.87 | F10 (0.51) | F2F10F7PLAUPRSS1 | |
| SCHEMBL23775703 | 0.87 | F2 (0.55) | F2F10F7PLAUPRSS1 | |
| Acetic Acid SCHEMBL5440440 | 0.87 | PLAU (0.49) | F2F10F7PLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL30387135 | 0.86 | F2 (0.50) | F2F10F7PLAUPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1681511-A | Combinations of drugs for the treatment of neoplasms | COMBINATORX INC (US) | 2005-10-12 | — | — | CN | claimed |
| EP-0973750-B1 | SUBSTITUTED BENZIMIDAZOLES AND THEIR USE FOR TREATING RETROVIRAL INFECTION | UNIV NORTH CAROLINA (US) | 2004-04-21 | — | — | EP | claimed |
| EP-0831832-B1 | METHODS OF COMBATTING INFECTIOUS DISEASES USING DICATIONIC BIS-BENZIMIDAZOLES | UNIV NORTH CAROLINA (US) | 2003-12-17 | — | — | EP | claimed |
| US-7875614-B2 | compounds for treatment of tumors | MERCK PATENT GMBH (DE) | 2011-01-25 | — | — | US | disclosed |
| US-20080194569-A1 | Phthalazinones | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20050137185-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INCORPORATED | 2005-06-23 | — | — | US | disclosed |
| US-5667975-A | Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans | THE UNIVERSITY OF NORTH CAROLINA | 1997-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194569-A1 | Phthalazinones | RB1, H1-3, H1-2 | F2 1365/4885F10 2112/4885F7 1287/4885 |
| US-20050137185-A1 | Combinations of drugs for the treatment of neoplasms | MKI67, DHFR, IL5 | F2 3796/4885F10 4118/4885F7 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.